Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

Migraine Clinical Trial

Official title:

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02964741
• Other study ID #: HUM00107286
• Secondary ID: R01NS094413
• Status: Terminated
• Phase: N/A
• Start date: February 22, 2017
• Est. completion date: August 1, 2021

Study information

• Verified date: July 2022
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates whether non-invasive brain stimulation, given for 20 minutes/once per day for ten days (M-F) can reduce migraine pain. Thirty patients will receive this treatment, while thirty will receive a "sham" procedure. Up to thirty healthy volunteers will be asked to undergo baseline assessments only (imaging, but no brain stimulation). Healthy volunteer data may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]).

Description:

Migraine is a debilitating chronic condition that affects most of the patient's existence, from childhood to late adulthood. During frequent headache attacks, its sufferers show marked increased sensitivity to noxious (hyperalgesia) and even non-noxious stimuli, a phenomenon called cutaneous allodynia that affects 63% of the patients. Although MRI-based techniques have provided insights into some brain mechanisms of migraine, many questions regarding its molecular impact in the brain are still unanswered. The overall goal of this project is to provide a detailed understanding of the µ-opioid receptor mediated transmission in the brain of migraine patients, one of the most important central pain regulatory systems in humans, with the long-term objective of developing more focused neuromechanism-driven methods for migraine research and therapy.

Preliminary studies from an earlier project (NINDS-NIHK23 NS0629946) using positron emission tomography (PET) with [11C] carfentanil, a selective radiotracer for μ-opioid receptor (μOR), have indicated that there is a decrease in µOR availability (non-displaceable binding potential; BPND) in the brain of migraine patients during the headache attacks and allodynia, including areas like thalamus and periaqueductal gray matter (PAG). µOR BPND is an objective measurement, in vivo, of endogenous μ-opioid availability, and its acute reduction reflects the activation of this neurotransmitter system. This is arguably one of the neuromechanisms most centrally involved in pain regulation, affecting multiple elements of the pain experience. Moreover, MRI-based reports have found that those findings co-localize with neuroplastic changes in migraine patients. Conventional therapies are unable to selectively target those dysfunctional brain regions, and there is a paucity of data on how to reverse embedded neuroplastic molecular mechanisms when available medications and surgical therapies fail. Several studies with motor cortex stimulation (MCS) have shown that epidural electrodes in the primary motor cortex (M1) are effective in providing analgesia in patients with refractory central. The rationale for MCS stimulation is based in part on the thalamic dysfunction noticed in chronic pain and migraine, and also on studies demonstrating that MCS significantly changes thalamic activity. Evidently, the invasive nature of such a procedure limits its indication to highly severe chronic pain disorders. New non-invasive brain neuromodulatory methods for M1, such as transcranial direct current stimulation (tDCS), can now safely modulate and activate the µOR system, providing relatively lasting pain relief in chronic pain patients and migraine. However, the electric fields generated by its most conventional analgesic montage are widely spread across the brain, lacking specificity on the pain-related structures directly targeted. Recently, a novel high-definition tDCS (HD-tDCS) montage created by our group was able to reduce exclusively "contralateral" sensory-discriminative clinical pain measures (pain intensity/area) in chronic patients by targeting more precisely the putative M1 region. It is hoped that this montage will provide durable relief of pain for this episodic migraine population.

This is a phase 2, single center, two-arm, double-masked, randomized investigation and modulation of the µ-opioid mechanisms in migraine (in vivo). We will enroll 60 patients with episodic migraine (30 for the active M1 HD-tDCS group and 30 for a sham group). Each participant will undergo a sequence of events and evaluations that will include baseline assessments, 10 days of HD-tDCS, pre- and post-PET and MRI scans, and questionnaires to evaluate pain and quality of life.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 44
• Est. completion date: August 1, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Episodic migraine (ICHD-3-beta) for at least 6 months, with at least one attack per month and less than 15 attacks per month

• No intake of opiate medication for the past six months

• No overuse of analgesic medication, defined as regular intake on =15 days per month for more than 3 months

• Willing to limit the introduction of new treatments for headache management

Exclusion Criteria:

• Presence of any other systemic or chronic pain disorder

• History or current evidence of a psychotic disorder (e.g. schizophrenia) or substance abuse; bipolar or severe major depression, as evidenced by Beck Depression score of = 30

• History of neurological disorder (e.g. epilepsy, stroke, neuropathy, neuropathic pain)

• Prior use of tDCS

• Current use of opioid pain medications

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• Active Comparator
non-invasive brain stimulation (active protocol)
• Sham Comparator
non-invasive brain stimulation (sham protocol)

Locations

Country	Name	City	State
United States	University of Michigan School of Dentistry	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days With Moderate-to-severe Headache	Moderate to severe headache is defined by the pain over 3 in an Numeric Rating Scale (NRS) ranging from 0 to 10 between end of treatment and one month follow-up.	End of treatment - over 1 month follow-up
Primary	Responder Rate	Number of participants who showed a 50% reduction of days with moderate-to-severe headache compared to baseline.	End of treatment - over 1 month follow-up
Secondary	Change in Pain Intensity Level Measured by the Visual Analog Scale in Migraineurs (Active or Sham)	Visual Analog Scale measures pain on a 0 to 10 scale, where 0 is "no pain" and 10 is "worst possible pain"	Approximately 45 days (Screening Visit [Original Baseline] to Follow Up #2 [28-days post-HD-tDCS treatment])
Secondary	Moderate to Severe Headache	Percentage of participants having moderate-to-severe headache between end of treatment and one month follow-up.; Defined as a response greater than 3 on the (0-10) NRS scale	End of treatment - over 1 month follow-up
Secondary	Use of Rescue Medication	Percentage of participants who used rescue medication between end of treatment and one month follow-up	End of treatment - over 1 month follow-up
Secondary	Change in Mu-opioid Receptor Non-displaceable Binding Potential (BPND) in the Brains of Migraineurs During Sustained Thermal Pain Threshold Stress Challenge Subsequent to Treatment by HD-tDCS (Active or Sham).	Mu-opioid receptor BPND at PET #2 will be subtracted from mu-opioid receptor BPND at PET #1.; PET #1 occurs during the week before HD-tDCS treatment begins. PET #2 occurs during the week after the final HD-tDCS treatment is completed.	Time between PET #1 and PET #2 is typically 21 days (minimum 17 days; maximum 42 days).
Secondary	Change in Mu-opioid Receptor Non-displaceable Binding Potential (BPND) in the Brains of Migraineurs at Rest Subsequent to Treatment by HD-tDCS (Active or Sham).	Mu-opioid receptor BPND at PET #2 will be subtracted from mu-opioid receptor BPND at PET #1.; PET #1 occurs during the week before HD-tDCS treatment begins. PET #2 occurs during the week after the final HD-tDCS treatment is completed.	Time between PET #1 and PET #2 is typically 21 days (minimum 17 days; maximum 42 days).